GWP.L Regulatory News (GWP)

18 Jan 2010 17:27



GW Pharmaceuticals PLC ("GW Pharmaceuticals"): 

Porton Down, UK, 18 January 2010: GW Pharmaceuticals (AIM: GWP)  hereby provides notification that application has been made to the London Stock Exchange for admission to trading on AIM in respect of a block listing of 400,000 ordinary shares of 0.1p each ("New Ordinary Shares").

The New Ordinary Shares will be issued from time to time pursuant to the exercise of employee share options under the Company's Executive Share Option Scheme 2001. On exercise the shares will be issued credited as fully paid and will rank pari passu with the existing ordinary shares in issue.

It is expected that such admission will become effective on 22 January 2010. 

For further information, please contact:

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

Piper Jaffray Ltd (Nominated Adviser)

Neil Mackison/Rupert Winckler +44 (0) 203 142 8700

Notes to Editors:

About GW Pharmaceuticals

GW Pharmaceuticals was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For more information, visit www.gwpharm.com